HALO
Halozyme Therapeutics Inc.

4,830
Loading...
Loading...
News
all
press releases
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·3h ago
News Placeholder
More News
News Placeholder
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
Zacks·23h ago
News Placeholder
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Zacks·9d ago
News Placeholder
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks·11d ago
News Placeholder
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Zacks·18d ago
News Placeholder
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.
Zacks·21d ago
News Placeholder
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Zacks·22d ago
News Placeholder
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·22d ago
News Placeholder
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Zacks·23d ago
News Placeholder
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Zacks·23d ago

Latest HALO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.